These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

300 related articles for article (PubMed ID: 34164452)

  • 1. Adoptive Natural Killer Cell Immunotherapy for Canine Osteosarcoma.
    Kisseberth WC; Lee DA
    Front Vet Sci; 2021; 8():672361. PubMed ID: 34164452
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preclinical evaluation and first-in-dog clinical trials of PBMC-expanded natural killer cells for adoptive immunotherapy in dogs with cancer.
    Razmara AM; Farley LE; Harris RM; Judge SJ; Lammers M; Iranpur KR; Johnson EG; Dunai C; Murphy WJ; Brown CT; Rebhun RB; Kent MS; Canter RJ
    J Immunother Cancer; 2024 Apr; 12(4):. PubMed ID: 38631708
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Natural Killer Cell Immunotherapy for Osteosarcoma.
    Tullius BP; Setty BA; Lee DA
    Adv Exp Med Biol; 2020; 1257():141-154. PubMed ID: 32483737
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Radiotherapy enhances natural killer cell cytotoxicity and localization in pre-clinical canine sarcomas and first-in-dog clinical trial.
    Canter RJ; Grossenbacher SK; Foltz JA; Sturgill IR; Park JS; Luna JI; Kent MS; Culp WTN; Chen M; Modiano JF; Monjazeb AM; Lee DA; Murphy WJ
    J Immunother Cancer; 2017 Dec; 5(1):98. PubMed ID: 29254507
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prospects and Advances in Adoptive Natural Killer Cell Therapy for Unmet Therapeutic Needs in Pediatric Bone Sarcomas.
    Bareke H; Ibáñez-Navarro A; Guerra-García P; González Pérez C; Rubio-Aparicio P; Plaza López de Sabando D; Sastre-Urgelles A; Ortiz-Cruz EJ; Pérez-Martínez A
    Int J Mol Sci; 2023 May; 24(9):. PubMed ID: 37176035
    [TBL] [Abstract][Full Text] [Related]  

  • 6. NK Cell Adoptive Immunotherapy of Cancer: Evaluating Recognition Strategies and Overcoming Limitations.
    Sanchez CE; Dowlati EP; Geiger AE; Chaudhry K; Tovar MA; Bollard CM; Cruz CRY
    Transplant Cell Ther; 2021 Jan; 27(1):21-35. PubMed ID: 33007496
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Enhancing Natural Killer Cell Targeting of Pediatric Sarcoma.
    Omer N; Nicholls W; Ruegg B; Souza-Fonseca-Guimaraes F; Rossi GR
    Front Immunol; 2021; 12():791206. PubMed ID: 34804076
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Natural killer cells for osteosarcoma.
    Tarek N; Lee DA
    Adv Exp Med Biol; 2014; 804():341-53. PubMed ID: 24924184
    [TBL] [Abstract][Full Text] [Related]  

  • 9. NK cell-based cancer immunotherapy: from basic biology to clinical application.
    Li Y; Yin J; Li T; Huang S; Yan H; Leavenworth J; Wang X
    Sci China Life Sci; 2015 Dec; 58(12):1233-45. PubMed ID: 26588912
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Application of Natural Killer Cell Immunotherapy for the Treatment of Cancer.
    Rezvani K; Rouce RH
    Front Immunol; 2015; 6():578. PubMed ID: 26635792
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Natural killer cells as a promising therapeutic target for cancer immunotherapy.
    Kim N; Lee HH; Lee HJ; Choi WS; Lee J; Kim HS
    Arch Pharm Res; 2019 Jul; 42(7):591-606. PubMed ID: 30895524
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Aerosol Delivery of Interleukin-2 in Combination with Adoptive Transfer of Natural Killer Cells for the Treatment of Lung Metastasis: Methodology and Effect.
    Kiany S; Gordon N
    Methods Mol Biol; 2016; 1441():285-95. PubMed ID: 27177675
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Natural Killer and T Cell Infiltration in Canine Osteosarcoma: Clinical Implications and Translational Relevance.
    Razmara AM; Judge SJ; Gingrich AA; Cruz SM; Culp WTN; Kent MS; Rebhun RB; Canter RJ
    Front Vet Sci; 2021; 8():771737. PubMed ID: 34869744
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative Immunogenomics of Canine Natural Killer Cells as Immunotherapy Target.
    Gingrich AA; Reiter TE; Judge SJ; York D; Yanagisawa M; Razmara A; Sturgill I; Basmaci UN; Brady RV; Stoffel K; Murphy WJ; Rebhun RB; Brown CT; Canter RJ
    Front Immunol; 2021; 12():670309. PubMed ID: 34594320
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cancer Immunotherapy Based on Natural Killer Cells: Current Progress and New Opportunities.
    Hu W; Wang G; Huang D; Sui M; Xu Y
    Front Immunol; 2019; 10():1205. PubMed ID: 31214177
    [TBL] [Abstract][Full Text] [Related]  

  • 16. NCR1 Expression Identifies Canine Natural Killer Cell Subsets with Phenotypic Similarity to Human Natural Killer Cells.
    Foltz JA; Somanchi SS; Yang Y; Aquino-Lopez A; Bishop EE; Lee DA
    Front Immunol; 2016; 7():521. PubMed ID: 27933061
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Approaches to Enhance Natural Killer Cell-Based Immunotherapy for Pediatric Solid Tumors.
    Quamine AE; Olsen MR; Cho MM; Capitini CM
    Cancers (Basel); 2021 Jun; 13(11):. PubMed ID: 34199783
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The immunotherapy of canine osteosarcoma: a historical and systematic review.
    Wycislo KL; Fan TM
    J Vet Intern Med; 2015; 29(3):759-69. PubMed ID: 25929293
    [TBL] [Abstract][Full Text] [Related]  

  • 19. NK Cell-Based Immunotherapy in Cancer Metastasis.
    Lorenzo-Herrero S; López-Soto A; Sordo-Bahamonde C; Gonzalez-Rodriguez AP; Vitale M; Gonzalez S
    Cancers (Basel); 2018 Dec; 11(1):. PubMed ID: 30597841
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Activated and expanded natural killer cells target osteosarcoma tumor initiating cells in an NKG2D-NKG2DL dependent manner.
    Fernández L; Valentín J; Zalacain M; Leung W; Patiño-García A; Pérez-Martínez A
    Cancer Lett; 2015 Nov; 368(1):54-63. PubMed ID: 26276724
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.